Médecine

Paramédical

Autres domaines


S'abonner

Emerging pharmacotherapies for COVID-19 - 18/06/20

Doi : 10.1016/j.biopha.2020.110267 
Rachana Salvi, Panini Patankar
 Department of Pharmacology & Therapeutics, Seth GSMC & KEM Hospital, Mumbai, 400012, India 

Corresponding author.

Bienvenue sur EM-consulte, la référence des professionnels de santé.
Article gratuit.

Connectez-vous pour en bénéficier!

Graphical abstract




Le texte complet de cet article est disponible en PDF.

Highlights

Corona Virus Disease 19 (COVID 19) is caused by novel corona virus (nCoV) & leads to respiratory failure in susceptible individuals.
Many drugs have been repurposed and are potentially used either prophylactically or therapeutically throughout the world.
SOLIDARITY trial by WHO promotes clinical trial with respect to four potentially useful repurposed medications.
The drugs mentioned in SOLIDARITY trial are mainly antivirals except for hydroxychloroquine which is an anti-malarial drug.
Convalescent plasma therapy is an evolving therapy based on the principle of passive immunity.
Cytokine storm are believed to lead to deterioration in patients and drugs against the same are also in research.

Le texte complet de cet article est disponible en PDF.

Abstract

Novel Corona-virus Disease 2019 (nCOVID 19) is caused by a novel virulent corona virus and leads to potentially fatal virulent pneumonia and severe respiratory distress syndrome. It was initially declared as public health emergency if international concern by WHO followed by Pandemic on 12th March 2020. As of 10th April 2020, more than 1.5 million people are affected globally with around 95,000 deaths. Vaccines for this deadly virus are currently under development and many drugs used for other indications have been repurposed and investigated for prophylaxis and treatment of COVID 19. As per SOLIDARITY trial by WHO, some of the most promising candidates include chloroquine phosphate and hydroxychloroquine which are anti-malarial medications, Remdesivir, Lopinavir-Ritonavir combination with or without interferon which are anti-HIV drugs and convalescent plasma therapy. The current evidence of efficacy and ongoing research has been elaborated in the article. Besides, there has been evidence regarding inflammatory pathogenesis of this virus leading to cytokine storm in susceptible individuals. Thus, anti-proinflammatory cytokine drugs like Anakinra and Tocilizumab are undergoing multiple trials and some results are encouraging. Similarly, use of anti-inflammatory cytokines like IL-37 and IL-38 is hypothesised to be useful and is under research. The situation is still evolving and hence there is yet no definitive therapy but to conclude the use of repurposed medications can be a boon till a definitive therapy and vaccines are developed.

Le texte complet de cet article est disponible en PDF.

Keywords : Chloroquine, Hydroxychloroquine, Remdesivir


Plan


© 2020  The Authors. Publié par Elsevier Masson SAS. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 128

Article 110267- août 2020 Retour au numéro
Article précédent Article précédent
  • Cardioprotective effects of melatonin: Focusing on its roles against diabetic cardiomyopathy
  • Yan-Jun Song, Chong-Bin Zhong, Wei Wu
| Article suivant Article suivant
  • Is combined medication with natural medicine a promising therapy for bacterial biofilm infection?
  • Lulu Zhang, Enjun Liang, Yungchi Cheng, Tariq Mahmood, Feng Ge, Ke Zhou, Mei Bao, Lang Lv, Li Li, Jianfeng Yi, Cheng Lu, Yong Tan

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.